DLX6-AS1: a putative lncRNA candidate in multiple human cancers.

IF 4.5 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Expert Reviews in Molecular Medicine Pub Date : 2021-11-26 DOI:10.1017/erm.2021.17

Mohsen Sheykhhasan, Yaghoub Ahmadyousefi, Reihaneh Seyedebrahimi, Hamid Tanzadehpanah, Hamed Manoochehri, Paola Dama, Nashmin Fayazi Hosseini, Mohammad Akbari, Mohsen Eslami Farsani

{"title":"DLX6-AS1: a putative lncRNA candidate in multiple human cancers.","authors":"Mohsen Sheykhhasan, Yaghoub Ahmadyousefi, Reihaneh Seyedebrahimi, Hamid Tanzadehpanah, Hamed Manoochehri, Paola Dama, Nashmin Fayazi Hosseini, Mohammad Akbari, Mohsen Eslami Farsani","doi":"10.1017/erm.2021.17","DOIUrl":null,"url":null,"abstract":"<p><p>Long non-coding RNAs (lncRNAs) have important roles in regulating the expression of genes and act as biomarkers in the initial development of different cancers. Increasing research studies have verified that dysregulation of lncRNAs occurs in various pathological processes including tumorigenesis and cancer progression. Among the different lncRNAs, DLX6-AS1 has been reported to act as an oncogene in the development and prognoses of different cancers, by affecting many different signalling pathways. This review summarises and analyses the recent research studies describing the biological functions of DLX6-AS1, its overall effect on signalling pathways and the molecular mechanisms underlying its action on the expression of genes in multiple human cancers. Our critical analysis suggests that different signalling pathways associated to this lncRNA may be used as a biomarker for diagnosis, or targets of treatment in cancers.</p>","PeriodicalId":50462,"journal":{"name":"Expert Reviews in Molecular Medicine","volume":"23 ","pages":"e17"},"PeriodicalIF":4.5000,"publicationDate":"2021-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Reviews in Molecular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/erm.2021.17","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 12

Abstract

Long non-coding RNAs (lncRNAs) have important roles in regulating the expression of genes and act as biomarkers in the initial development of different cancers. Increasing research studies have verified that dysregulation of lncRNAs occurs in various pathological processes including tumorigenesis and cancer progression. Among the different lncRNAs, DLX6-AS1 has been reported to act as an oncogene in the development and prognoses of different cancers, by affecting many different signalling pathways. This review summarises and analyses the recent research studies describing the biological functions of DLX6-AS1, its overall effect on signalling pathways and the molecular mechanisms underlying its action on the expression of genes in multiple human cancers. Our critical analysis suggests that different signalling pathways associated to this lncRNA may be used as a biomarker for diagnosis, or targets of treatment in cancers.

查看原文本刊更多论文

DLX6-AS1:多种人类癌症的推定lncRNA候选者

长链非编码rna (Long non-coding RNAs, lncRNAs)在调节基因表达方面具有重要作用，并在不同癌症的早期发展中作为生物标志物。越来越多的研究证实，lncrna的失调发生在多种病理过程中，包括肿瘤发生和癌症进展。在不同的lncrna中，据报道，DLX6-AS1通过影响许多不同的信号通路，在不同癌症的发展和预后中作为致癌基因。本文综述并分析了近年来有关DLX6-AS1的生物学功能、对信号通路的总体影响及其在多种人类癌症中影响基因表达的分子机制的研究进展。我们的批判性分析表明，与该lncRNA相关的不同信号通路可能用作癌症诊断的生物标志物或治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Reviews in Molecular Medicine BIOCHEMISTRY & MOLECULAR BIOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL

CiteScore

7.40

自引率

1.60%

发文量

期刊介绍： Expert Reviews in Molecular Medicine is an innovative online journal featuring authoritative and timely Reviews covering gene therapy, immunotherapeutics, drug design, vaccines, genetic testing, pathogenesis, microbiology, genomics, molecular epidemiology and diagnostic techniques. We especially welcome reviews on translational aspects of molecular medicine, particularly those related to the application of new understanding of the molecular basis of disease to experimental medicine and clinical practice.